#NEWS:?Today we announced the first participant has been dosed in a Phase 1a #clinicaltrial of ABI-6250, our investigational candidate in development for chronic hepatitis delta virus. Read more about today’s news and our work to address this critical unmet need: https://lnkd.in/es3fh6V3 #HepD #HDV #hepatitis #virology #innovation #biotechnology #milestone
Assembly Biosciences, Inc.
生物技术研究
South San Francisco，California 6,055 位关注者
Passionate about making a profound impact on patients’ lives
关于我们
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com. Assembly is headquartered in South San Francisco.
- 网站
-
https://www.assemblybio.com
Assembly Biosciences, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，California
- 类型
- 上市公司
- 创立
- 2014
- 领域
- HBV Cure、Anti-Viral、Hepatitis B和Herpesvirus
地点
Assembly Biosciences, Inc.员工
动态
-
#NEWS: Today we reported positive interim Phase 1a results from ABI-1179, an investigational long-acting helicase-primase inhibitor in development for recurrent genital herpes, a therapeutic area where no new innovation has been made in decades. Read more: https://lnkd.in/ejbMc6q5 #HSV #genitalherpes #herpes #herpesvirus #innovation #virology #STI
-
-
#NEWS: Today we reported interim results from a Phase 1b clinical trial of our next-generation capsid assembly modulator ABI-4334 in chronic hepatitis B virus (HBV). Read more: https://lnkd.in/gATQbjQU #HBV #clinicaltrials #innovation
-
-
#NEWS: Today we announced $30.1M in equity investment and accelerated funding from Gilead Sciences to advance our clinical development programs for serious viral diseases. Learn more: https://lnkd.in/gZNeXJEP #partnership #collaboration #innovation
-
-
#NEWS: Today we announced Q3?financial?results,?recent company updates,?and upcoming anticipated #milestones?for?our pipeline?of #herpesvirus?and #hepatitis?candidates. Learn more: https://lnkd.in/etsc8nWX #FinancialResults #genitalherpes #biotechnews?$ASMB
-
-
On National Herpes Awareness Day today – and every day – we are committed to spotlighting the urgent need for innovation and development of new therapies for individuals with recurrent genital herpes. Check out resources from Herpes Cure Advocacy at www.herpescureadvocacy.com to take action and get involved. #herpes #herpesawarenessday #HSV #MedEd
-
-
#NEWS: Today we announced positive interim results from a Phase 1a clinical trial of our long-acting helicase-primase inhibitor candidate ABI-5366. Read the press release: https://lnkd.in/gZJKjD_J #innovation #clinicaltrials #HSV #herpes
-
-
#NEWS: Today we announced Q2 2024 financial results and recent company highlights. Read more here: https://bit.ly/4dwgIAa #Q2Results #CompanyNews #FinancialResults $ASMB
-
-
#DYK approximately 50% of people with initial symptomatic genital herpes infection have three or more recurrences per?year? We’re aiming to?develop improved?therapeutic options for those living with recurrent?genital herpes. Learn what sets Assembly apart in our research and development: https://lnkd.in/eRJfaN-S #innovation #HSV #herpes #biotechnews
-
-
At Assembly, we are focused on developing innovative treatments for serious viral diseases, including hepatitis B and D. This #WorldHepatitisDay, we are working under urgent conditions. According to a 2024 World Health Organization report, outcomes for the millions living with chronic #hepatitis infections remain poor.?Learn more about the changing landscape of #hepatitis worldwide: https://lnkd.in/gHkaKSNv #LiverDisease #HBV #HepB #HDV
-